Dr. Sanjiv Agarwala to Present Update on Provectus' PV-10
Monday March 8, 2010
Participating In The Seventh International Symposium On Melanoma And Other Cutaneous Malignancies On March 12, 2010 In New York City

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that Dr. Sanjiv Agarwala, Principal Investigator for Provectus' Phase 2 PV-10 trial site at St. Luke's Hospital & Health Network in Bethlehem, PA, will present an update on the Company's ongoing Phase 2 trial of PV-10 for metastatic melanoma at the Seventh International Symposium on Melanoma and Other Cutaneous Malignancies on March 12, 2010, in New York City.

Dr. Agarwala's presentation, "Chemoablation in Melanoma: An Update," will be presented during the session entitled "Unique Approaches to Melanoma Therapy."

Craig Dees, Ph.D., CEO of Provectus said, "We look forward to Dr. Agarwala's update to the medical community on the clinical progress that has been made with PV-10 for metastatic melanoma since last year's conference. From our research, we believe that PV-10 is proving to have great promise as a safe and effective therapeutic for this devastating cancer that affects so many people each year, and for which there are few viable treatments. Dr. Agarwala's presentation should highlight many of the reasons we are excited about the data from PV-10's clinical trials."

According to the American Cancer Society, there were over 68,000 new cases of melanoma, and over 8,600 deaths in the U.S. in 2009. Further, the World Health Organization has estimated that 48,000 patients globally died from melanoma in 2008.

About The Seventh International Symposium on Melanoma and Other Cutaneous Malignancies

The Seventh International Symposium on Melanoma and Other Cutaneous Malignancies will continue a strong history and provide participants with a comprehensive overview of state-of-the-art care of patients with these diseases. Specific topics to be highlighted at this symposium include current risk assessment factors and diagnostic technologies, new prognostic and predictive biomarkers with clinical potential for individualizing treatment, and promising emerging systemic immunotherapies, targeted therapies, and regional therapies for advanced melanoma and other cutaneous malignancies. These topics and the implications for practice will be presented by leading experts in the treatment of these different tumor types. This interactive symposium will also cover practical issues concerning surgical management and adjuvant therapy for these patients. These concepts and practical diagnostic issues will be further reinforced through 2 interactive case-based discussion sessions with the faculty to provide expert insights into their application in practice. Throughout the symposium, participants will also learn about currently accruing high-priority trials and the relevant patient eligibility criteria to enhance enrollment into trials evaluating novel therapeutic regimens in the adjuvant and advanced disease settings for melanoma and other cutaneous malignancies.

About Provectus Pharmaceuticals, Inc. (www.pvct.com)

Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies. Its lead oncology agent, PV-10, is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing systemic side effects. Its oncology focus is on melanoma, breast cancer and metastatic liver cancer. The Company has received orphan drug designation from the FDA for its melanoma indication. Its lead dermatological drug, PH-10, also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed enrollment in three of its Phase 2 trials -- PV-10 as a therapy for metastatic melanoma, and PH-10 as a topical treatment for atopic dermatitis and for psoriasis. It has also recently initiated a Phase 1 trial for PV-10 for liver cancer. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus please visit the Company's website at www.pvct.com or contact Porter, LeVay & Rose, Inc.

FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.

SOURCE: Provectus Pharmaceuticals, Inc.

Contact:

Provectus Pharmaceuticals, Inc.
Peter R. Culpepper, CFO, 866-594-5999 #30
or
Porter, LeVay & Rose, Inc.
Marlon Nurse, 212-564-4700
VP - Investor Relations
or
Bill Gordon, 212-564-4700
SVP - Media Relations